Pharmaceutical effluent can change sharply between batches, cleaning cycles and product campaigns. Memva develops treatment trains around the actual wastewater profile—combining pretreatment, biological treatment, membrane polishing and concentrate management only where they are needed.
A pharmaceutical plant may discharge synthesis residues, solvents, cleaning water, salts, active pharmaceutical ingredients (APIs) and high-strength organic streams from different production areas. The difficult part is often the combination: a stream can have high COD and still be poorly biodegradable, or appear treatable until salinity or toxicity disrupts the biological stage.
That is why a fixed “AOP + MBR + RO” package is not automatically the right answer. The practical route is to first identify which streams should be segregated, what can be biologically degraded, what needs oxidation or physicochemical pretreatment, and whether the final target is discharge, reuse, or zero liquid discharge.
These are the conditions that most often determine whether conventional biological treatment will be stable—or whether pretreatment, stream segregation or advanced polishing is needed.
Solvents, aromatic compounds and complex synthesis by-products can keep COD high even when ordinary biological treatment is operating normally.
Residual active ingredients may require source control, oxidation or a carefully managed biological stage rather than relying on dilution alone.
Salt from synthesis, neutralization and washing can reduce biological activity and also affect the recovery and operating pressure of membrane systems.
Flow, pH, COD and toxicity may change by production campaign. Equalization and controlled feeding can be as important as the downstream process itself.
A robust system may use several barriers, but not every plant needs every step. The sequence below shows how the treatment train is typically organized from source control to final polishing.
Separate unusually strong or incompatible streams where practical, then buffer flow, pH and organic load before treatment.
Use pH adjustment, solids removal, coagulation or advanced oxidation when toxicity or refractory organics would otherwise limit the biological stage.
Remove biodegradable organics and ammonia while retaining biomass and producing a low-solids effluent suitable for further polishing.
Reduce dissolved salts and remaining contaminants when reuse quality or tighter discharge limits require an additional barrier.
Where discharge of concentrate is restricted, evaluate further concentration, evaporation, crystallization or a ZLD configuration.
The same flow rate can require a very different system depending on biodegradability, salinity, toxicity and the final water-quality target.
| Wastewater condition | What it affects | Typical design response |
|---|---|---|
| High COD, low BOD/COD | Biological removal may be slow or incomplete. | Characterize the refractory fraction first; consider oxidation, physicochemical pretreatment, anaerobic treatment or source segregation where appropriate. |
| Antibiotics / API residues | Can create toxicity or persistent residuals. | Review source segregation and pretreatment; use oxidation or biological acclimation only after treatability is understood. |
| High TDS / conductivity | Can inhibit biomass and increase membrane pressure. | Balance salt-tolerant biological operation with membrane recovery, concentrate handling and—if required—thermal concentration. |
| Large batch fluctuations | Shock loads can destabilize downstream treatment. | Increase equalization, improve online monitoring and control the feed rate to the biological or oxidation stage. |
| Water reuse target | Discharge-quality water may still be unsuitable for process reuse. | Add polishing based on the reuse point: filtration, RO and other finishing steps may be required for cooling, boiler or process-water applications. |
| ZLD requirement | Liquid concentrate cannot leave the facility as a normal wastewater stream. | Design the membrane recovery and brine concentration stages together; evaporation and crystallization may be needed depending on salt chemistry and disposal constraints. |
A meaningful first design discussion does not need a perfect data package, but it does need more than “500 m³/day of pharma wastewater.”
Flow and COD tell only part of the story. The values below help determine whether the project needs stronger equalization, oxidation, a biological stage, membrane polishing or a separate concentrate-management route.
The original project data describes wastewater from antibiotic and anti-inflammatory drug production with a nominal treatment capacity of 500 m³/day. The main operating challenge was a high and variable organic load combined with toxicity to conventional activated sludge.
| Parameter | Influent | Treated water |
|---|---|---|
| COD | 8,500–12,000 mg/L | < 50 mg/L |
| BOD₅ | 3,500 mg/L | < 10 mg/L |
| NH₃-N | 450 mg/L | < 1.0 mg/L |
Project figures are wastewater-specific and should not be treated as guaranteed performance for another plant. Final process selection and achievable effluent quality depend on the actual feed composition, operating conditions and required standard.
A useful budget cannot be based on flow alone. Two plants treating the same daily volume can have very different CAPEX and OPEX when COD strength, salinity, chemical consumption, membrane recovery and concentrate disposal are different.
COD mass loading affects reactor volume, oxygen demand, sludge production and the amount of pretreatment required before biological treatment.
If refractory compounds require Fenton, ozone or other oxidation, reagent dose and reaction conditions can become a major operating-cost factor.
Higher water recovery can reduce discharge volume, but it also increases concentrate strength. Pretreatment quality, scaling potential and cleaning frequency matter.
ZLD, evaporation or off-site disposal can dominate lifecycle cost when salts and non-biodegradable residuals are concentrated into a smaller waste stream.
The questions below are usually more useful at the project stage than a generic equipment list.
There is no single process that fits every pharmaceutical plant. High-strength biodegradable wastewater may need a different route from a saline synthesis stream containing refractory organics or antibiotic residues. The process should be selected after reviewing flow, COD/BOD, salinity, toxicity, key chemicals and the required discharge or reuse target.
Sometimes it can remove a meaningful fraction, but not reliably for every compound. If the wastewater contains poorly biodegradable or inhibitory compounds, source segregation, advanced oxidation or another pretreatment step may be needed before the biological stage. Treatability testing is the safest way to avoid over-designing or under-designing the system.
AOP is most useful when it solves a specific problem—for example reducing toxicity, breaking down refractory organics or improving biodegradability before biological treatment. It should not be added automatically because reagent consumption and operating cost depend heavily on the wastewater matrix.
The first step is to understand where the salt comes from and whether high-TDS streams can be segregated. Depending on concentration and discharge requirements, the design may combine salt-tolerant biological operation with RO, high-recovery membrane treatment, evaporation or other concentrate-management steps.
An MBR keeps biomass in the biological system while producing low-suspended-solids effluent. That can support stable organic and ammonia removal and also provide a cleaner feed for downstream membrane polishing. Its performance still depends on toxicity, salinity, biodegradability and loading conditions.
RO is typically considered when dissolved salts or residual dissolved contaminants must be reduced further, especially for reuse applications or tighter final-water specifications. It creates a concentrate stream, so concentrate disposal or further treatment needs to be considered at the same time.
ZLD is generally driven by site discharge restrictions, water-recovery goals or concentrate-disposal constraints. A ZLD design normally combines high water recovery with a route for concentrating and handling the remaining dissolved solids; the exact configuration depends on salt chemistry and the final solids-disposal plan.
Send whatever is available: average and peak flow, COD/BOD, TDS or conductivity, ammonia, pH, temperature, major solvents or APIs, current treatment steps and the required discharge or reuse target. If some laboratory values are missing, the known production and wastewater information is still useful for the first review.
A useful first review can usually start with a flow rate, a few laboratory values and the final water-quality target. You do not need to have every parameter available before getting in touch.
Share the information you have. The more specific the feed and target are, the more useful the first technical discussion will be.
Pharmaceutical wastewater treatment performance varies by wastewater composition, operating conditions and regulatory target. Final design should be based on project-specific water analysis and process evaluation.